Showing results (171-180 of 181) with videos related to
Sort By:
Pageof 19
Molecular Autism|January 2, 2020
Increased Ca<sup>2+</sup> signaling in <i>NRXN1α</i><sup></sup> neurons derived from ASD induced pluripotent stem cellsSahar Avazzadeh, Katya McDonagh, Jamie Reilly, et al.BMC Neuroscience|September 16, 2021
NRXN1α<sup>+/-</sup> is associated with increased excitability in ASD iPSC-derived neuronsSahar Avazzadeh, Leo R Quinlan, Jamie Reilly, et al.Cancer Discovery|April 22, 2021
Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in CancerClare F Malone, Neekesh V Dharia, Guillaume Kugener, et al.Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.JAMA Dermatology|September 18, 2024
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical TrialsEric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, et al.Dermatitis : Contact, Atopic, Occupational, Drug|January 10, 2025
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension TrialEric L Simpson, Lawrence F Eichenfield, Kim A Papp, et al.American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.The New England Journal of Medicine|August 13, 2016
Two Phase 3 Trials of Adalimumab for Hidradenitis SuppurativaAlexa B Kimball, Martin M Okun, David A Williams, et al.JAMA Dermatology|May 3, 2023
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical TrialMatthew J Zirwas, Zoe D Draelos, Janet DuBois, et al.Arxiv|February 24, 2025
<i>KMT2B</i>-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulationLaura Cif, Diane Demailly, Jean-Pierre Lin, et al.Pageof 19